Kalaimathi B1, Mohamed Ilyas Rahamathulla M2, Mohana Lakshmi M3, Alexander Gnana Durai W. J4, Saravana Jothi R5, Priyadharshini R6, Jeevitha K7
BACKGROUND
To compare and analyse the metabolic side effects of Risperidone and Haloperidol in newly diagnosed drug-naive schizophrenic disorder patients attending Govt. Stanley Medical College Hospital during initial 6 months of therapy.
MATERIALS AND METHODS
Newly diagnosed drug-naïve Schizophrenic Patients (n = 60) aged between 18 - 45 years are recruited and randomly allocated into Group A (Risperidone 4 - 6 mg daily) and Group B (Haloperidol 5 - 10 mg daily) after getting informed consent from the patient’s family members. Patients are followed up monthly for the occurrence of metabolic abnormalities like weight gain, rise in blood pressure, elevated fasting, post-prandial blood sugar level, dyslipidaemia for a period of 6 months.
RESULTS
Risperidone group showed the mean body weight increase from 64.40 to 69.27, SBP/DBP increase from 123.80/79 to 129.90/83.13; FBS/PPBS increase from 100.20/129.30 to 135.40/185.00; TC increase from 177.23 to 206.23; LDL from 124.30 to 158.30; HDL 48.83 to 50.07; TG 133.47 to 197.83: Haloperidol group showed the mean body weight increase from 64.07 to 68.48, SBP/DBP increase from 123.80/79.00 to 124.27/81.67; FBS/PPBS increase from 100.20/129.30 to 119.87/167.10; TC increase from 177.23 to 197.40; LDL from 119.77 to 139.00; HDL remained 48.83; TG 133.47 to 171.40.
CONCLUSION
This study showed that patients in both the groups had weight gain, rise in blood sugar, LDL cholesterol and Triglycerides level, but the rise was significant in patients on Risperidone when compared to those on Haloperidol during the 6-month followup.
KEYWORDS
Metabolic Side Effects, Drug Naïve Patients, Risperidone, Haloperidol.
